ABL partners with KaliVir Immunotherapeutics to advance development of oncolytic viruses
ABL and Coave Therapeutics enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy
AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund II
Nosopharm signs partnership with INRAE and University of Montpellier to develop new anti-infectives
Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
Tollys and Gustave Roussy enter into new research agreement
Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer
Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis
